NCT05205811View on ClinicalTrials.gov

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

June 19, 2025

Study Completion Date

October 20, 2025

Conditions
Smoking Cessation
Interventions
DRUG

Bupropion

Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.

DRUG

Zonisamide

Zonisamide (100 mg/daily) for 7 weeks.

DRUG

Placebo bupropion

Placebo bupropion for 7 weeks.

DRUG

Placebo zonisamide

Placebo zonisamide for 7 weeks.

OTHER

E-cigarette

e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.

Trial Locations (2)

27617

Rose Research Center, Raleigh

28262

Rose Research Center, Charlotte

All Listed Sponsors
collaborator

Foundation for a Smoke Free World INC

OTHER

lead

Rose Research Center, LLC

INDUSTRY

NCT05205811 - The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette | Biotech Hunter | Biotech Hunter